Free Trial

Editas Medicine Q4 2024 Earnings Report

Editas Medicine logo
$1.16 -0.09 (-6.80%)
As of 12:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Editas Medicine EPS Results

Actual EPS
-$0.55
Consensus EPS
-$0.39
Beat/Miss
Missed by -$0.16
One Year Ago EPS
-$0.23

Editas Medicine Revenue Results

Actual Revenue
$30.60 million
Expected Revenue
$37.17 million
Beat/Miss
Missed by -$6.57 million
YoY Revenue Growth
N/A

Editas Medicine Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Remove Ads

Editas Medicine Earnings Headlines

Zacks Research Estimates Editas Medicine FY2027 Earnings
The unusual signal flashing green again
Something fascinating happened in April... While a lot of Wall Street institutions were opening new positions in a falling stock, something different showed up on my screen. A special set of candles had just turned green - signaling the kind of momentum surge I'd seen only a handful of times before. What happened next? The stock soared 45% on the underlying stock in just a few weeks and 227% for anyone who traded the options. Naturally, there would have been smaller wins and those that would not have worked out, but this wasn't some penny stock or crypto play… It was ARM Holdings - a major semiconductor player that had just shed 9% of its value.
Editas Medicine CFO Erick Lucera to step down, Amy Parison to succeed
See More Editas Medicine Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Editas Medicine? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Editas Medicine and other key companies, straight to your email.

About Editas Medicine

Editas Medicine (NASDAQ:EDIT), a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

View Editas Medicine Profile

More Earnings Resources from MarketBeat